Work

Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study.

Year: 2019

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2019.37.15_suppl.4583

Authors: Ronan Flippot, Bradley Alexander McGregor, Abdallah Flaifel, Kathryn P. Gray, Sabina Signoretti, John A. Steinharter, Eliezer Mendel Van Allen, Meghara K. Walsh, Katy Gundy, Xiao X. Wei, Lauren Christine Harshman, Ulka N. Vaishampayan, Toni K. Choueiri, Rana R. McKay

Institutions: Dana-Farber Cancer Institute, Brigham and Women's Hospital, Wayne State University, Harvard University, Dana-Farber Brigham Cancer Center

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2946936611

Cites:

Cited by: 13

Related to: 10